<DOC>
	<DOCNO>NCT00099658</DOCNO>
	<brief_summary>Infection Streptococcal pneumoniae common invasive bacterial infection HIV infect child . The purpose study determine safety immune response pneumococcal polysaccharide-protein conjugate vaccine ( PncCV ) HIV infect uninfected child . The study also determine safety immune response Haemophilus influenzae vaccine ( HibCV ) child . Recruitment study occur two hospital South Africa , HIV infect infant participate study must also coenrolled CIPRA SA-Project 2 study .</brief_summary>
	<brief_title>Safety Immune Response Pneumococcal Vaccine ( PncCV ) HIV Infected Uninfected Children</brief_title>
	<detailed_description>HIV infect child high risk invasive pneumococcal disease ( IPD ) cause bacterium Streptococcus pneumoniae . Chemoprophylaxis use child certain disease prevention IPD , drug resistance may develop prevention strategy . In contrast , vaccine prevent IPD would fewer negative implication future treatment option chemoprophylaxis . This study evaluate safety immune response PncCV South African HIV infect uninfected child . This study also evaluate safety immune response HibCV child . This study last 5.5 year . There 5 group study . Group 1 HIV uninfected infant bear HIV uninfected mother . Group 2 HIV infect infant CDC Disease Category 1 randomly assign delay therapy arm ( Arm 1 ) CIPRA SA-Project 2 . Group 3 HIV infect infant CDC Disease Category 1 randomly assign first early therapy arm ( Arm 2 ) CIPRA SA-Project 2 . Group 4 HIV infect infant CDC Disease Category 2 3 randomly assign second early therapy arm ( Arm 3 ) CIPRA SA-Project 2 . Group 5 HIV uninfected infant bear HIV infected mother ; Group 5 infant undergo repeat HIV test 4 8 month age , 9 11 month age , approximately 18 month age . There 13 study visit ; medical history assessment , physical examination , blood collection occur visit . At 3 study visit age 24 week , participant receive injection PncCV injection routine pediatric vaccine , include HibCV . Previously vaccinate HIV infected participant receive vaccine need complete South African series routine pediatric vaccination . Within group , participant randomly assign receive booster shot either PncCV HibCV 64 76 week age . Participants also receive two measles vaccination 38 76 week age . Parents guardian ask complete diary card vaccination report adverse effect occur within 72 hour post-vaccination .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria All Infants : Birth weight least 2 kg ( 4.4 lb ) Written informed consent parent guardian Mother 's HIV status document 24th week pregnancy , infant join Group 5 HIV uninfected Parent guardian infant intend remain study area duration trial Inclusion Criteria HIV Infected Infants : HIV infect Participating CIPRA SAProject 2 Exclusion Criteria All Infants : Blood product prior study entry Immunosuppressant agents 2 week , within 1 week study entry Unable tolerate oral medication Presence major , lifethreatening congenital defect Acute illness fever require hospitalization within 72 hour immunization Grade 2 vaccinerelated allergic reaction Grade 3 4 clinical laboratory toxicity relate vaccination Use antiretroviral therapy allow CIPRA SAProject 2 . Infants receive antiretroviral drug use prevent mothertoinfant HIV transmission eligible study . Use investigational drug , systemic cytotoxic chemotherapy , interleukin immune modulators Require certain medication Exclusion Criteria HIV Uninfected Infants : Vaccines prior study entry . Infants receive bacille CalmetteGuerin oral polio vaccine exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>MTCT</keyword>
</DOC>